- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Epix Medical gets public support
MRI contrast agent developer Epix Medical successfully launchedan initial public offering on Jan. 30, netting $13 million fromthe sale of 2 million shares. Initially offered at $7, the stockclosed at $8.75 on Feb. 12.The Cambridge, MA-based company's
MRI contrast agent developer Epix Medical successfully launchedan initial public offering on Jan. 30, netting $13 million fromthe sale of 2 million shares. Initially offered at $7, the stockclosed at $8.75 on Feb. 12.
The Cambridge, MA-based company's main product is MS-325, an MRIcontrast agent designed for the diagnosis of vascular diseases,including coronary artery disease and peripheral vascular disease(SCAN 12/18/96). Epix, formerly known as Metasyn, has formed strategicalliances to develop and commercialize MS-325 with contrast agentproducers Mallinckrodt and Daiichi.
New CT Angiography Study Shows Impact of COVID-19 on Coronary Inflammation and Plaque
February 5th 2025Prior COVID-19 infection was associated with a 28 percent higher progression of total percent atheroma volume (PAV) annually and over a 5 percent higher incidence of high-risk plaque in patients with coronary artery lesions, according to CCTA findings from a new study.
